Items Tagged ‘BTD’

October 25th, 2016

Tecentriq® Improves NSCLC Survival Compared to Chemotherapy Regardless of PD-L1 Status


Tecentriq® (atezolizumab) improves the outcomes of individuals with advanced non-small cell lung cancer (NSCLC) according to the results of a pivotal clinical trial presented at the European Society of Medical Oncology (ESMO) 2016 Annual Meeting this week. Tecentriq is an agent that stimulates the immune system to recognize and mount an immune attack against cancer […]

View full entry

Tags: 2016, atezolizumab, BTD, ESMO, General Lung Cancer, Lung Cancer, Lung Cancer - Non-Small Cell, monoclonal antibody, News, nsclc, PD-L1, Recurrent Lung Cancer - Non-Small Cell